SCHEMBL8285181

SCHEMBL8285181

Cc1cc(C(=O)CC(C)C)nc2c1c(=O)cc(Nc1ccccc1)n2-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE11A Q9HCR9 1/20 0.42
HPGD P15428 4/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 2/20 0.35
GSK3B P49841 2/20 0.35
CSF1R P07333 1/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
KMT2A Q03164 1/20 0.34
RELA Q04206 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 2/20 0.33
GFER P55789 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8287518 0.89 PDE11A (0.44) PDE11AHPGDLMNAPOLBGSK3B
SCHEMBL8285174 0.87 PDE11A (0.43) PDE11AHPGDPOLBGSK3BCSF1R
SCHEMBL8285223 0.87 PDE11A (0.44) PDE11AHPGDLMNAPOLBGSK3B
SCHEMBL5872175 0.87 PDE11A (0.47) PDE11AHPGDLMNAPOLBGSK3B
SCHEMBL5871541 0.86 PDE11A (0.46) PDE11AHPGDLMNAPOLBGSK3B
SCHEMBL8285228 0.85 PDE11A (0.42) PDE11AHPGDLMNAPOLBCSF1R
SCHEMBL8287397 0.85 PDE11A (0.46) PDE11AHPGDLMNAPOLBGSK3B
SCHEMBL8287393 0.85 PDE11A (0.46) PDE11AHPGDLMNAPOLBKDM4E
SCHEMBL8285167 0.85 PDE11A (0.41) PDE11AHPGDLMNAPOLBCSF1R
SCHEMBL8286401 0.84 PDE11A (0.42) PDE11AHPGDLMNAPOLBGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005091857-A2 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2005-10-06 WO disclosed